NEO Relative Valuation
NEO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NEO is overvalued; if below, it's undervalued.
Historical Valuation
Neogenomics Inc (NEO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.69. The fair price of Neogenomics Inc (NEO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：12.06
Fair
81.19
PE
1Y
3Y
5Y
Trailing
Forward
34.59
EV/EBITDA
Neogenomics Inc. (NEO) has a current EV/EBITDA of 34.59. The 5-year average EV/EBITDA is 120.87. The thresholds are as follows: Strongly Undervalued below -2510.75, Undervalued between -2510.75 and -1194.94, Fairly Valued between 1436.67 and -1194.94, Overvalued between 1436.67 and 2752.48, and Strongly Overvalued above 2752.48. The current Forward EV/EBITDA of 34.59 falls within the Historic Trend Line -Fairly Valued range.
-22.73
EV/EBIT
Neogenomics Inc. (NEO) has a current EV/EBIT of -22.73. The 5-year average EV/EBIT is -26.09. The thresholds are as follows: Strongly Undervalued below -126.78, Undervalued between -126.78 and -76.44, Fairly Valued between 24.25 and -76.44, Overvalued between 24.25 and 74.59, and Strongly Overvalued above 74.59. The current Forward EV/EBIT of -22.73 falls within the Historic Trend Line -Fairly Valued range.
2.01
PS
Neogenomics Inc. (NEO) has a current PS of 2.01. The 5-year average PS is 4.44. The thresholds are as follows: Strongly Undervalued below -2.45, Undervalued between -2.45 and 1.00, Fairly Valued between 7.88 and 1.00, Overvalued between 7.88 and 11.33, and Strongly Overvalued above 11.33. The current Forward PS of 2.01 falls within the Historic Trend Line -Fairly Valued range.
55.41
P/OCF
Neogenomics Inc. (NEO) has a current P/OCF of 55.41. The 5-year average P/OCF is -123.10. The thresholds are as follows: Strongly Undervalued below -577.06, Undervalued between -577.06 and -350.08, Fairly Valued between 103.89 and -350.08, Overvalued between 103.89 and 330.87, and Strongly Overvalued above 330.87. The current Forward P/OCF of 55.41 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Neogenomics Inc. (NEO) has a current P/FCF of 0.00. The 5-year average P/FCF is -61.96. The thresholds are as follows: Strongly Undervalued below -310.82, Undervalued between -310.82 and -186.39, Fairly Valued between 62.47 and -186.39, Overvalued between 62.47 and 186.90, and Strongly Overvalued above 186.90. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Neogenomics Inc (NEO) has a current Price-to-Book (P/B) ratio of 1.86. Compared to its 3-year average P/B ratio of 1.84 , the current P/B ratio is approximately 1.21% higher. Relative to its 5-year average P/B ratio of 2.69, the current P/B ratio is about -30.75% higher. Neogenomics Inc (NEO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -2.74%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.39% , the current FCF yield is about -100.00% lower.
1.87
P/B
Median3y
1.84
Median5y
2.69
-1.09
FCF Yield
Median3y
-2.74
Median5y
-3.39
Competitors Valuation Multiple
The average P/S ratio for NEO's competitors is , providing a benchmark for relative valuation. Neogenomics Inc Corp (NEO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 11.90%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NEO decreased by 26.15% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -10.55 to -14.45.
The secondary factor is the Revenue Growth, contributed 11.90%to the performance.
Overall, the performance of NEO in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Neogenomics Inc (NEO) currently overvalued or undervalued?
What is Neogenomics Inc (NEO) fair value?
How does NEO's valuation metrics compare to the industry average?
What is the current P/B ratio for Neogenomics Inc (NEO) as of Dec 05 2025?
What is the current FCF Yield for Neogenomics Inc (NEO) as of Dec 05 2025?
What is the current Forward P/E ratio for Neogenomics Inc (NEO) as of Dec 05 2025?